CN1043405C - 含杂环酰胺衍生物的药物组合物的制备方法 - Google Patents

含杂环酰胺衍生物的药物组合物的制备方法 Download PDF

Info

Publication number
CN1043405C
CN1043405C CN91111566A CN91111566A CN1043405C CN 1043405 C CN1043405 C CN 1043405C CN 91111566 A CN91111566 A CN 91111566A CN 91111566 A CN91111566 A CN 91111566A CN 1043405 C CN1043405 C CN 1043405C
Authority
CN
China
Prior art keywords
shape
pharmaceutical compositions
chemical compound
composition
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN91111566A
Other languages
English (en)
Chinese (zh)
Other versions
CN1062291A (zh
Inventor
J·J·霍洛汉
I·J·爱德华斯
R·J·蒂姆科
R·J·布雷德韦
A·克莱门茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca UK Ltd
Syngenta Ltd
Original Assignee
Zeneca Ltd
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26298105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1043405(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909027014A external-priority patent/GB9027014D0/en
Priority claimed from GB919115107A external-priority patent/GB9115107D0/en
Application filed by Zeneca Ltd, Imperial Chemical Industries Ltd filed Critical Zeneca Ltd
Publication of CN1062291A publication Critical patent/CN1062291A/zh
Application granted granted Critical
Publication of CN1043405C publication Critical patent/CN1043405C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN91111566A 1990-12-12 1991-12-11 含杂环酰胺衍生物的药物组合物的制备方法 Expired - Lifetime CN1043405C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB909027014A GB9027014D0 (en) 1990-12-12 1990-12-12 Pharmaceutical agents
GB9027014.1 1990-12-12
GB9115107.6 1991-07-12
GB919115107A GB9115107D0 (en) 1991-07-12 1991-07-12 Pharmaceutical agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN98121369A Division CN1105705C (zh) 1990-12-12 1998-10-14 一种特定物理形态的杂环酰胺衍生物的制备方法

Publications (2)

Publication Number Publication Date
CN1062291A CN1062291A (zh) 1992-07-01
CN1043405C true CN1043405C (zh) 1999-05-19

Family

ID=26298105

Family Applications (2)

Application Number Title Priority Date Filing Date
CN91111566A Expired - Lifetime CN1043405C (zh) 1990-12-12 1991-12-11 含杂环酰胺衍生物的药物组合物的制备方法
CN98121369A Expired - Lifetime CN1105705C (zh) 1990-12-12 1998-10-14 一种特定物理形态的杂环酰胺衍生物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN98121369A Expired - Lifetime CN1105705C (zh) 1990-12-12 1998-10-14 一种特定物理形态的杂环酰胺衍生物的制备方法

Country Status (30)

Country Link
US (6) US5319097A (enExample)
EP (1) EP0490648B1 (enExample)
JP (1) JP2585495B2 (enExample)
KR (2) KR0183027B1 (enExample)
CN (2) CN1043405C (enExample)
AP (1) AP285A (enExample)
AT (1) ATE131048T1 (enExample)
AU (1) AU656157B2 (enExample)
BE (1) BE1004229A5 (enExample)
CA (2) CA2056066C (enExample)
CZ (1) CZ283181B6 (enExample)
DE (2) DE4140858A1 (enExample)
DK (1) DK0490648T3 (enExample)
ES (1) ES2079589T3 (enExample)
FI (1) FI101193B1 (enExample)
FR (1) FR2670488B1 (enExample)
GB (2) GB2280606B (enExample)
GR (1) GR3018318T3 (enExample)
HK (2) HK81597A (enExample)
HU (2) HU213211B (enExample)
IE (1) IE75348B1 (enExample)
IL (1) IL100091A (enExample)
IT (1) IT1256282B (enExample)
MX (1) MX9102473A (enExample)
MY (1) MY106315A (enExample)
NZ (1) NZ240939A (enExample)
PH (1) PH30928A (enExample)
RU (1) RU2106140C1 (enExample)
SK (2) SK279813B6 (enExample)
TW (1) TW276181B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
GB9119001D0 (en) * 1991-09-05 1991-10-23 Ici Plc Pharmaceutical agents
GR1001368B (el) * 1992-10-08 1993-10-29 Ici Plc Φαρμακευτικοί φορείς.
DE4235133A1 (de) * 1992-10-19 1994-04-21 Bayer Ag Kristallines (R)-(-)-2-Cycloheptyl-N-methylsulfonyl-[4-(2-chinolinyl-methoxy)-phenyl]-acetamid
DE9410461U1 (de) * 1994-07-01 1994-09-22 Merck Patent Gmbh, 64293 Darmstadt Mittel für die Röntgenfluoreszenzanalyse
US6279736B1 (en) 1995-04-19 2001-08-28 Capitol Specialty Plastics, Inc. Barrier pack having an absorbing agent applied to the interior of the pack
IN182496B (enExample) * 1996-02-20 1999-04-17 Reddy Research Foundation
US6630496B1 (en) 1996-08-26 2003-10-07 Genetics Institute Llc Inhibitors of phospholipase enzymes
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
GB9726735D0 (en) * 1997-12-18 1998-02-18 Zeneca Ltd Pharmaceutical compositions
US6828344B1 (en) 1998-02-25 2004-12-07 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6500853B1 (en) 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US6224907B1 (en) * 1998-03-06 2001-05-01 Alza Corporation Anti-asthma therapy
KR100283682B1 (ko) * 1998-07-14 2001-03-02 조정래 열풍건조장치
US6253463B1 (en) 1999-04-26 2001-07-03 Niro A/S Method of spray drying
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
JP2003529549A (ja) * 1999-09-20 2003-10-07 アルザ・コーポレーション 医薬の結晶多形変換を減少させるための方法
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof
IL140096A0 (en) * 2000-12-05 2002-02-10 Internat Specialty Products Is Process for preparation of zafirlukast
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
SK288217B6 (sk) 2001-01-26 2014-08-05 Merck Sharp & Dohme Corp. Zmes, terapeutická kombinácia, farmaceutický prostriedok a ich použitie
BRPI0206641B8 (pt) 2001-01-26 2021-05-25 Merck Sharp & Dohme uso de um inibidor da absorção de esteróis
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
JP2005502628A (ja) * 2001-07-10 2005-01-27 ファルマシア・アンド・アップジョン・カンパニー 結晶性チアジンオキサゾリジノン
CZ2004196A3 (cs) 2001-08-15 2005-01-12 Pharmacia & Upjohn Company Krystaly obsahující sůl N-[2-(diethylamino)ethyl]-5-[(5-fluor-2-oxo-3H-indol-3-yliden) methyl]-2,4-dimethyl-1H-pyrrol 3-karboxamidu s kyselinou jablečnou, způsob jejich výroby a kompozice na jejich bázi
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
DE60216300T2 (de) 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003291719A1 (en) 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ES2311806T3 (es) * 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
CN1756756A (zh) * 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
CA2517573C (en) 2003-03-07 2011-12-06 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
MY142017A (en) * 2004-03-19 2010-08-16 Nestec Sa Composition comprising all essential nutrients of a fruit or a plant material with increased stability and bioavailability and process of forming the same
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
US20070197467A1 (en) * 2006-02-06 2007-08-23 Srinivasulu Rangineni Zafirlukast compositions
US20090012146A1 (en) * 2007-07-02 2009-01-08 Giridhar Reddy Buggana Solubility-enhanced pharmaceutical compositions comprising zafirlukast
AU2008282295A1 (en) * 2007-07-30 2009-02-05 Auspex Pharamaceuticals, Inc. Substituted indoles
US20090149662A1 (en) * 2007-12-05 2009-06-11 Raghupathi Reddy Anumula Processes for preparing zafirlukast
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US20160339010A1 (en) 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CA3052071A1 (en) 2017-01-30 2018-08-02 Western New England University Thiol isomerases inhibitors and use thereof
US10752585B2 (en) 2017-12-28 2020-08-25 Council Of Scientific & Industrial Research Process for the preparation of Zafirlukast and analogs thereof
CA3219671A1 (en) 2021-05-19 2022-11-24 Thomas Christian Lines Quercetin-containing compositions for use in treating amyotrophic lateral sclerosis
EP4518852A1 (en) 2022-05-06 2025-03-12 Quercis Pharma AG Method for treating cancers and neurological diseases using quercetin-containing compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199543A2 (en) * 1985-04-17 1986-10-29 Ici Americas Inc. Heterocyclic amide derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027018D0 (en) * 1990-12-12 1991-01-30 Ici Plc Heterocyclic compounds
IL100091A (en) * 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0199543A2 (en) * 1985-04-17 1986-10-29 Ici Americas Inc. Heterocyclic amide derivatives

Also Published As

Publication number Publication date
KR0183027B1 (ko) 1999-05-01
IL100091A (en) 1998-08-16
EP0490648A1 (en) 1992-06-17
KR100207802B1 (ko) 1999-07-15
BE1004229A5 (fr) 1992-10-13
KR970005014A (ko) 1997-01-29
US5612367A (en) 1997-03-18
NZ240939A (en) 1994-05-26
CZ283181B6 (cs) 1998-01-14
SK279813B6 (sk) 1999-04-13
US5319097A (en) 1994-06-07
FI101193B (fi) 1998-05-15
FR2670488A1 (fr) 1992-06-19
CN1243827A (zh) 2000-02-09
SK279814B6 (sk) 1999-04-13
AP285A (en) 1993-09-23
AU8899491A (en) 1992-06-18
AU656157B2 (en) 1995-01-27
HK81397A (en) 1997-06-27
FR2670488B1 (fr) 1994-01-28
RU2106140C1 (ru) 1998-03-10
US5993859A (en) 1999-11-30
GB9126354D0 (en) 1992-02-12
FI101193B1 (fi) 1998-05-15
HU211126A9 (en) 1995-10-30
IE914310A1 (en) 1992-06-17
EP0490648B1 (en) 1995-12-06
HUT61281A (en) 1992-12-28
DK0490648T3 (da) 1996-05-06
DE4140858A1 (de) 1992-06-17
FI915826A0 (fi) 1991-12-11
US6143775A (en) 2000-11-07
GB2251791B (en) 1995-05-17
JP2585495B2 (ja) 1997-02-26
GB9418154D0 (en) 1994-10-26
CA2056066A1 (en) 1992-06-13
MX9102473A (es) 1992-06-01
DE69115229D1 (de) 1996-01-18
US5482963A (en) 1996-01-09
ITMI913324A1 (it) 1993-06-11
TW276181B (enExample) 1996-05-21
HU913865D0 (en) 1992-02-28
GB2280606A (en) 1995-02-08
GR3018318T3 (en) 1996-03-31
PH30928A (en) 1997-12-23
AP9100340A0 (en) 1992-01-31
HK81597A (en) 1997-06-27
HU213211B (en) 1997-03-28
GB2251791A (en) 1992-07-22
CA2056066C (en) 2002-04-02
IL100091A0 (en) 1992-08-18
CA2319308A1 (en) 1992-06-13
CN1062291A (zh) 1992-07-01
CA2319308C (en) 2001-08-21
ES2079589T3 (es) 1996-01-16
KR920011493A (ko) 1992-07-24
GB2280606B (en) 1995-05-17
IT1256282B (it) 1995-11-29
ATE131048T1 (de) 1995-12-15
US5504216A (en) 1996-04-02
JPH04266824A (ja) 1992-09-22
CN1105705C (zh) 2003-04-16
DE69115229T2 (de) 1996-05-09
FI915826L (fi) 1992-03-31
MY106315A (en) 1995-04-29
ITMI913324A0 (it) 1991-12-11
IE75348B1 (en) 1997-08-27
CS375691A3 (en) 1992-06-17

Similar Documents

Publication Publication Date Title
CN1043405C (zh) 含杂环酰胺衍生物的药物组合物的制备方法
FI82376B (fi) Foerfarande foer framstaellning av tvaofasiga, fasta laekemedelspreparat.
CN105121434A (zh) 坎格列净一水合物及其晶型、它们的制备方法和用途
CN1646490A (zh) 新的阿托韦兹他汀半钙结晶以及制备它们的方法,以及新的制备阿托韦兹他汀半钙形式ⅰ,ⅷ和ⅸ的方法
CN1633439A (zh) 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙
WO2009084023A2 (en) Amorphous ramelteon and process for the preparation thereof
CN104045615B (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用
CN100341495C (zh) 格列本脲固体分散体、口服组合物及其制备方法
AU3095600A (en) New pharmaceutical formulation
US20080014263A1 (en) Amorphous eprosartan mesylate and process for the preparation thereof
CN1617872A (zh) 三环型三唑并苯并氮杂䓬衍生物的非晶态物质
WO2008110339A2 (en) Polymorphs of rivastigmine hydrogentartrate
CN101033211A (zh) 5－氯－4－羟基－2(1h)－吡啶酮晶型及其制备方法和应用
CN1698623A (zh) 无结晶型态的抗乙肝病毒药物分散组合物及其药物制剂
WO2005034919A2 (en) Method of producing dosage units of a solid drug form containing warfarin sodium salt as active component
US20070299123A1 (en) Amorphous frovatriptan succinate and process for the preparation thereof
CN104045614B (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型c及其制备方法和应用
FI106021B (fi) Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi
CN1903869A (zh) 替比夫定的衍生物盐及其制备方法和药物应用
CN1257478A (zh) 用作抗－心律不齐药物的硝基苯甲酰胺
CN1528766A (zh) 草酸阿地福韦酯及其晶型和制备方法及用途
PT100508B (pt) Composicoes farmaceuticas e processo para a sua preparacao

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: London, England

Applicant after: ZENECA Ltd.

Address before: England

Applicant before: Imperial Chemical Industries PLC

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: IMPERIAL CHEMICAL CORPORATION TO: ZENECA LTD

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA (UK) LIMITED

Free format text: FORMER OWNER: SIGENTIS CO., LTD.

Effective date: 20061222

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: SIGENTIS CO., LTD.

Free format text: FORMER NAME OR ADDRESS: ZENECA LTD

CP03 Change of name, title or address

Address after: surrey

Patentee after: SYNGENTA LTD.

Address before: London, England

Patentee before: ZENECA Ltd.

TR01 Transfer of patent right

Effective date of registration: 20061222

Address after: London, England

Patentee after: ASTRAZENECA UK LTD.

Address before: surrey

Patentee before: SYNGENTA LTD.

C17 Cessation of patent right
CX01 Expiry of patent term

Expiration termination date: 20111211

Granted publication date: 19990519